Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
MorphoSys
Pharma
2024's top biopharma M&A deals
Despite a return to dealmaking grandeur in 2023, the biopharma industry’s appetite for large-scale mergers and acquisitions was notably more muted in 2024.
Fraiser Kansteiner
,
Zoey Becker
,
Angus Liu
,
Kevin Dunleavy
,
Eric Sagonowsky
Jan 13, 2025 3:00am
Novartis to close 2 MorphoSys sites, lay off 330 staffers
Dec 19, 2024 9:47am
PharmaEssentia nabs MorphoSys alum for CCO role
Dec 6, 2024 9:48am
Incyte eyes label expansion for Monjuvi after phase 3 win
Aug 16, 2024 11:23am
Incyte picks up full Monjuvi rights from MorphoSys for $25M
Feb 6, 2024 9:59am
Novartis eyes MorphoSys buyout: Reuters
Feb 5, 2024 3:39pm
